TopStocks Alert: (Nasdaq:CVKD)

July 15, 2026

Greetings Readers,

7 catalysts are stacking up on a Nasdaq biotech (CVKD) that most traders haven't discovered yet, and the setup is getting harder to ignore.

The company holds breakthrough Factor XIa inhibitors, the same drug class Bristol Myers Squibb, Johnson & Johnson, and Bayer are racing to dominate, plus a Phase 3-ready cardiovascular drug targeting populations with zero treatment alternatives.

Recently, the company announced a major pipeline expansion with the acquisition of VLX-1005, a first-in-class Phase 2 drug for Heparin-Induced Thrombocytopenia that already has Orphan Drug and Fast Track designations from the FDA.

Now add a low float of fewer than two million shares and analyst price targets above $30, and you'll see exactly why this profile has climbed to the top of my watchlist.

If you're looking for an under-the-radar biotech with meaningful catalysts lining up, this one demands immediate attention:

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Cadrenal Therapeutics is a biopharmaceutical company developing therapeutics to address serious gaps in anticoagulation therapy. The company's lead asset, tecarfarin, is an investigational oral vitamin K antagonist designed for patients who face higher risks when using warfarin, including those with implanted cardiac devices or severe kidney conditions.

Tecarfarin is engineered to provide more predictable anticoagulation and reduce risks associated with stroke, heart attack, clot formation, and treatment volatility. Its unique metabolic design allows it to bypass many of the complications that limit the effectiveness of traditional warfarin.

And based on multiple catalysts now taking shape, CVKD has secured a top position on my watchlist heading into 2026.

Here are the key catalysts coming into focus:

A low float that creates an environment of elevated volatility potential
A $45 analyst target pointing to triple digit upside
A $30 analyst target reaffirmed by another firm
A pipeline expanding acquisition that adds major Factor XIa inhibitors
Clinical trial initiation plans for a high risk ESKD population
A new high profile board appointment strengthening clinical leadership

Company Breakdown: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Cadrenal is a late stage cardiovascular drug developer focused on advancing tecarfarin, a novel vitamin K antagonist designed as a safer and more stable alternative to warfarin. The company is specifically targeting patient populations that currently have no reliable anticoagulation options beyond warfarin, despite significant risks.

Warfarin remains difficult to manage because of drug interactions, genetic variability, kidney involvement, and frequent dose adjustments. Many patients remain outside the therapeutic range, which increases the likelihood of heart attack, stroke, bleeding, and death.

Cadrenal aims to solve this.

Company Overview Video

Why Tecarfarin Could Be a Game Changer

Tecarfarin has a Phase 3 ready profile supported by extensive clinical data. Studies show potential improvements in anticoagulation stability, including increased time in therapeutic range. This is a critical measure because stability is strongly correlated with reduced adverse events.

Key distinctions include:

Orphan drug designation for LVAD patients
Orphan drug designation and fast track status for ESKD patients with AFib
A metabolic pathway independent of CYP450 isoenzymes
Reduced susceptibility to drug interactions and kidney impairment

Tecarfarin is also being developed for patients with mechanical heart valves who struggle with warfarin due to genetic resistance, kidney dysfunction, or polypharmacy issues.

Because tecarfarin is the only next generation VKA being developed for these specific populations, Cadrenal is aiming to redefine standards of care in areas where therapeutic options have not progressed for decades.

Tecarfarin's Metabolic Advantage

Tecarfarin Clinical Development Pipeline

Pipeline Expansion: Factor XIa and Frunexian

Cadrenal's acquisition of assets from eXIthera added significant depth to its anticoagulation pipeline. These assets include frunexian, a first in class IV Factor XIa inhibitor, and EP 7327, an oral Factor XIa inhibitor in development for major thrombotic indications.

Factor XIa has emerged as one of the most validated targets in cardiovascular drug development. It plays a limited role in normal clotting but a major role in pathological thrombosis. This makes FXIa inhibition a promising strategy for reducing clot formation while maintaining lower bleeding risk.

Large pharmaceutical companies have invested billions into this space, underscoring its long term commercial and scientific potential.

Frunexian Clinical Data

Frunexian is currently the only intravenous small molecule Factor XIa inhibitor in active development for acute use cases. Preclinical studies demonstrate potent antithrombotic activity with minimal bleeding complications.

Two Phase 1 clinical studies produced strong results:

aPTT increased in a dose proportional manner
PT remained unchanged, confirming target specificity
Factor XIa activity decreased consistently with dose
Frunexian was well tolerated at all tested levels

These characteristics make frunexian strategically valuable in settings where rapid anticoagulation control is critical, such as catheter procedures, bypass circuits, and device associated situations.

What This Means For Investors:

The clinical data shows frunexian works exactly as designed. Higher doses create stronger anticoagulation effects that can be turned on and off rapidly. Most importantly, Phase 1 trials in humans showed no bleeding events at any dose level tested, which has been the biggest challenge in anticoagulation drug development.

This gives Cadrenal a drug that hospitals can use during critical procedures like heart surgeries and catheter placements where precise, fast-acting blood thinning control is essential. Big Pharma has spent billions trying to develop drugs with this profile. Cadrenal just acquired one that's already proven safe and effective in human trials and showing the exact pharmacological characteristics that make it commercially valuable.

Frunexian PK and PD Results

Dose Dependent Factor XIa Inhibition

Source: Cadrenal Therapeutics Website

CVKD Potential Catalyst #1: Breaking News – VLX-1005 Acquisition Adds a Phase 2 HIT Treatment with FDA Designations

Cadrenal announced the acquisition of VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. This acquisition immediately strengthens the pipeline with a late-stage, first-in-class drug candidate that has already secured bothOrphan Drug Designation and Fast Track status from the FDA.

VLX-1005 is a novel inhibitor of 12-LOX, targeting a key immune signaling pathway that drives Heparin-Induced Thrombocytopenia (HIT). HIT is a potentially life-threatening complication that can occur in up to 5% of patients exposed to heparin — the most widely used parenteral anticoagulant. Approximately 300,000 patients in the U.S. are evaluated annually for suspected HIT, with an estimated56,000 confirmed diagnoses each year.

The clinical data backing VLX-1005 is compelling. Two Phase 1 studies demonstrated favorable tolerability with no deaths, no serious adverse events, and no concerning safety trends. A recent Phase 2 study also showed promising reductions in thromboembolic events — a preferred endpoint for regulators, clinicians, and payers.

What This Means For Investors: Cadrenal just acquired a Phase 2 asset addressing a$1 billion market opportunity across the U.S. and EU, targeting a condition with high mortality and no therapies that treat the underlying immune-driven biology. Importantly, VLX-1005 already has FDA designations that can accelerate development and enhance commercial value.

This acquisition is highly strategic because it aligns directly with Cadrenal's focus on the$40 billion global anticoagulation market. VLX-1005 targets complications arising from heparin use, complementing Cadrenal’s existing Factor XIa inhibitors and tecarfarin — giving the company multiple shots on goal across key thrombosis segments.

The deal structure is also investor-friendly. Veralox will receive milestone payments tied to clinical and regulatory achievements, plus royalties on future sales. This allows Cadrenal to preserve capital while advancing development — paying primarily as value is created.

Perhaps most importantly, VLX-1005 is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing. This is a novel mechanism with strong scientific rationale, positive human data, and regulatory support. Second-generation 12-LOX inhibitors are also being explored for type 1 diabetes and other immune-mediated diseases, suggesting meaningful platform expansion potential.

CVKD Potential Catalyst #2: A Low Float Could Create Heightened Volatility Potential

According to publicly available data, CVKD has roughly 1.7M shares in its float. Low float profiles are known for sharp movements when material news surfaces. With multiple catalysts on deck, this creates the possibility of amplified upside reactions.

CVKD Potential Catalyst #3: A Forty $45 Analyst Target Suggests Triple Digit Upside

Noble Capital Markets reiterated its $45 price target, which reflects more than two hundred percent upside from recent closing levels. The firm noted that Cadrenal's expanded pipeline and upcoming clinical trials strengthen the long term outlook for tecarfarin.

CVKD Potential Catalyst #4: Another Analyst Reiterates a $30 Price Target

Zacks Small Cap Research reaffirmed its $30 target, citing the strong partnership with Abbott for Phase 3 LVAD trials and the significant unmet need across the targeted populations. The firm highlighted that Abbott's involvement is a major advantage for Cadrenal's pivotal development strategy.

Source: Zacks Small Cap

CVKD Potential Catalyst #5: A Major Acquisition Strengthening the Pipeline

Cadrenal's acquisition of eXIthera's portfolio significantly broadened its anticoagulation capabilities. With both a VKA and Factor XIa inhibitors under development, Cadrenal is now one of the only companies targeting the full spectrum of cardiovascular thrombotic risk.

CVKD Potential Catalyst #6: Clinical Trial Initiation Plans Mark an Important Milestone

Cadrenal recently announced plans to initiate a tecarfarin study in ESKD patients transitioning to dialysis. This group faces some of the highest cardiovascular risks among all chronic disease populations. The initiation of this study is a pivotal step toward a registration pathway for ESKD plus AFib.

CVKD Potential Catalyst #7: A High Level Board Appointment Strengthens Clinical Leadership

Cadrenal announced that Dr. Lee Scott Golden, M.D., has joined its Board of Directors as an independent member. Dr. Golden currently serves as Chief Medical Officer at PTC Therapeutics and brings more than twenty five years of experience across rare disease, cardiovascular medicine, and late stage drug development.

His background includes senior roles at Pfizer, Actelion, Eisai, and multiple cardiovascular focused companies. Dr. Golden's expertise aligns directly with Cadrenal's development strategy, adding significant value as the company prepares for critical Phase 3 activities and regulatory interactions.

CVKD Recap: Seven Potential Breakout Catalysts

A low float that creates significant volatility potential
A $45 analyst target with triple digit upside
A $30 target reaffirmed by a second analyst
A pipeline expanding acquisition adding Factor XIa assets
Upcoming clinical trial initiation in ESKD
A high impact board appointment strengthening clinical leadership

Coverage is now officially underway on Cadrenal Therapeutics, Inc. (Nasdaq: CVKD). When updates become available, I will share them quickly. Talk soon.

Add Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) to your radar right now. The signals forming here suggest that a major shift could be approaching, and you will want to be ahead of it.

Enjoyed this breakdown?

Don't miss our next early stock alert.
Join our SMS list and get real time picks sent straight to your phone the moment we release them.

Get Instant SMS Alerts

Fast, free, zero spam. Opt out anytime.

By joining, you agree to receive recurring SMS alerts from TopStocks. Message and data rates may apply. Reply STOP to unsubscribe.

MASTER LEGAL DISCLAIMER

Last Updated: Apr 30, 2026

Publisher: Relqo Media LLC (Wyoming, United States)

Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

IMPORTANT SUMMARY, PLEASE READ FIRST

This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Penzance LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

1. NATURE AND INTENT OF THIS COMMUNICATION

Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company's operations or investment merit.

2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

Relqo Media LLC ("Relqo Media") has been engaged by Penzance LLC to provide promotional media and digital investor awareness services with respect to Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). The following details outline the nature, scope, and financial terms of this engagement:

Relqo Media received cash compensation of $25,000 for a 5 day campaign covering April 27th , 2026, through May 1st 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering March 9th , 2026, through March 13th 2026.
Relqo Media received cash compensation of $25,000 for a 4 day campaign covering March 1st , 2026, through March 5th 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 23rd , 2026, through february 28th 2026.
Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 18th , 2026, through february 23rd 2026.
Relqo Media received cash compensation of $25,000 for a 6 day campaign covering January 25th , 2026, through January 30th 2026.
Relqo Media received cash compensation of $25,000 for a 7 day campaign covering January 12, 2026, through January 19, 2026.
Relqo Media received cash compensation of $25,000 for a campaign covering December 10, 2025, through December 17, 2025.
Relqo Media received cash compensation of $25,000 for a campaign covering December 2, 2025, through December 10, 2025.
Relqo Media continued to receive cash compensation on a week to week basis at a rate of $25,000 per week, paid weekly, from July 26, 2025, through September 9, 2025, resulting in aggregate additional compensation of $150,000.
Relqo Media received additional cash compensation at the same weekly rate of $25,000 per week, paid weekly, covering the period from June 26, 2025, through July 26, 2025, resulting in aggregate compensation of $100,000.
Relqo Media received cash compensation from Penzance LLC for digital investor awareness and promotional services at a rate of $25,000 per week, paid weekly, beginning January 1, 2025, through July 1, 2025, resulting in aggregate compensation of $650,000 during that period.
Total Compensation: As of January 19, 2026, Relqo Media has received cumulative cash compensation of $975,000 from Penzance LLC for services rendered in connection with CVKD.
Future Compensation: This engagement continues on an open ended basis at a rate of $25,000 per week, paid weekly, until terminated by either party. Accordingly, Relqo Media will continue to receive compensation at this rate beyond January 19, 2026, unless and until such agreement is terminated or modified in writing.
Nature of Services: Relqo Media's services include, but are not limited to, creating, publishing, and distributing digital media, promotional articles, newsletters, websites, investor awareness content, social media campaigns, email/SMS marketing, and other investor-focused communications designed to raise awareness of CVKD among retail and institutional investors.
Conflict of Interest Statement: Because Relqo Media has been, and will continue to be, compensated directly by Penzance LLC for its services, this relationship represents a material conflict of interest. Relqo Media's communications regarding CVKD, including but not limited to newsletters, articles, press releases, advertisements, websites, emails, SMS alerts, and social media posts, should be understood as paid advertisements that are inherently biased.
Securities Ownership Disclosure: Penzance LLC and/or its affiliates, officers, directors, or associated individuals may own, acquire, or dispose of securities of Cadrenal Therapeutics, Inc. before, during, or after the campaign period. This means that while Relqo Media is being compensated to promote CVKD, the entities paying for such services may simultaneously engage in securities transactions involving CVKD stock, which could result in gains or losses to those parties independent of Relqo Media's activities.
Investor Warning: All readers, investors, and market participants should assume that any and all promotional communications disseminated by Relqo Media regarding CVKD are issued for the purpose of increasing investor awareness and may have the effect of increasing trading volume and/or the market price of CVKD's securities. Investors are strongly cautioned to conduct their own independent research, due diligence, and analysis of CVKD, including review of all filings made with the Securities and Exchange Commission (SEC), prior to making any investment decision.

This relationship creates a material conflict of interest. All content distributed by Relqo Media LLC regarding CVKD should be viewed as promotional, financially motivated, and inherently biased.

3. INTENDED AUDIENCE

These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.

Any and all information regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans, should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.

We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.

You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.

If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence, including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts, before making any investment decision.

5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

Historically, promotional campaigns for microcap and small-cap securities, particularly those driven by paid advertising, often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.

You should assume and expect that:

CVKD's share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
Once buying interest subsides, selling begins, or the promotion ends, which may occur suddenly and without notice, the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
These price and volume movements are not reflective of intrinsic value and may have no correlation to the company's actual fundamentals or long-term business prospects.

Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.

By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.

6. NO RELIANCE, INVESTOR RESPONSIBILITY

The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.

You are solely responsible for:

Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.

We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company's business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.

By viewing our materials, you agree that:

You will not rely solely on our communications in making an investment decision;
You accept full responsibility for conducting independent due diligence; and
Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.

7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE

Our materials may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will," "should," "could," "projects," "estimates," "potential," and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.

Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..

You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.

8. INFORMATION SOURCING, BIAS, AND ACCURACY

We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

Assume all information presented by Relqo Media is:

Subjective,
Not independently verified,
Created to highlight potential upside and omit downsides,
Not suitable as the basis for any investment decision.

9. OWNERSHIP AND TRADING CONFLICTS

Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

We use a range of outreach and promotional tools, including:

Email and newsletter distributions,
SMS/MMS text campaigns,
Social media posts and influencers,
Google and native display ads,
Press releases, video marketing, and paid content distribution.

By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

11. ADVERTISING LAW COMPLIANCE

Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC's interpretations of sponsored investment-related communications.

We make good-faith efforts to disclose all:

Compensation arrangements,
Conflicts of interest,
Risks,
Limitations of our role, and
The promotional nature of this content.

We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

12. NON-U.S. USERS

This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country's laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

All content is provided "as-is" and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

Investment losses,
Inaccuracies,
Technical delays,
User misunderstandings,
Omissions or errors in content.

Total liability for any claim shall not exceed one hundred dollars ($100).

14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

16. FINAL NOTICE, ACCEPTANCE OF TERMS

We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

If you do not accept all terms of this disclaimer in full, you must:

Exit our websites,
Unsubscribe from our communications,
Discontinue viewing all Relqo Media promotional content.

17. NO RELIANCE

By viewing or engaging with this content, you agree that:

You will not rely on any statements made by Relqo Media for investment purposes,
You waive any claim that our content was a material factor in your investment decision,
You have read, understood, and accepted this disclaimer in full.

Legal Contact: 📧 support@topstocks.com

Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.